SCHEMBL20060609

SCHEMBL20060609

Cc1ccc(-n2nc(C)cc2NC(=O)Nc2ccc(Oc3ccnc(NC(=O)CNC(=O)N4CCOCC4)c3)c3ccccc23)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 16/20 0.63
SRC P12931 11/20 0.63
MAPK12 P53778 10/20 0.63
GSK3A P49840 10/20 0.63
SYK P43405 8/20 0.63
HCK P08631 7/20 0.63
GSK3B P49841 2/20 0.63
MAPK13 O15264 2/20 0.54
MAPK11 Q15759 2/20 0.54
CIT O14578 1/20 0.53
MUSK O15146 1/20 0.53
MAP3K7 O43318 1/20 0.53
RIPK2 O43353 1/20 0.53
STK10 O94804 1/20 0.53
MAP4K4 O95819 1/20 0.53
CHEK2 O96017 1/20 0.53
ABL1 P00519 1/20 0.53
EGFR P00533 1/20 0.53
TNF P01375 1/20 0.53
RAF1 P04049 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12540692 0.93 MAPK14 (0.74) MAPK14SRCMAPK12GSK3ASYK
SCHEMBL20060614 0.90 MAPK14 (0.62) MAPK14SRCMAPK12GSK3ASYK
SCHEMBL20060611 0.89 MAPK14 (0.62) MAPK14SRCMAPK12GSK3ASYK
SCHEMBL20060665 0.87 MAPK14 (0.65) MAPK14SRCMAPK12GSK3ASYK
SCHEMBL20060661 0.86 MAPK14 (0.78) MAPK14SRCMAPK12GSK3ASYK
SCHEMBL12540337 0.86 MAPK14 (0.78) MAPK14SRCMAPK12GSK3ASYK
SCHEMBL20060669 0.85 MAPK12 (0.66) MAPK14SRCMAPK12GSK3ASYK
SCHEMBL20060634 0.85 MAPK14 (0.67) MAPK14SRCMAPK12GSK3ASYK
SCHEMBL14701833 0.85 MAPK14 (0.85) MAPK14SRCMAPK12GSK3ASYK
SCHEMBL20060663 0.84 MAPK14 (0.60) MAPK14SRCMAPK12GSK3ASYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2582433-B1 UREIDO-PYRAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF RHINOVIRUS INFECTIONS RESPIVERT LTD (GB) 2018-04-18 EP disclosed